The UK Modern Industrial Strategy makes Life Sciences one of its eight high-growth sectors, the IS-8, backed by over £2 billion of government funding. The ambition is for the UK to become Europe's leading life sciences economy by the end of the decade, and the sector could grow by £41 billion by 2035.
This page is our analysis of what that means for the engineering and manufacturing companies that supply life sciences, the device makers, diagnostics specialists, precision engineers, and cleanroom manufacturers, and what to do about it now. For the wider picture across all eight sectors, start with our UK Modern Industrial Strategy overview.
Why life sciences, and why now
The headline debates in life sciences are about drug pricing and biotech finance, but the opportunity for engineering and manufacturing suppliers is more concrete: the strategy is built to onshore critical manufacturing and reduce reliance on a small number of overseas suppliers. The sector generated over £108 billion in turnover in 2021 to 2022, and in 2023 the UK exported £25.6 billion of pharmaceutical products and £10.1 billion of medical technology. Every one of those depends on a supply chain of precision components, devices, diagnostics, and manufacturing capability.
If you make medical devices, precision components, diagnostics hardware, or work in cleanroom and regulated manufacturing, this is a sector with funding and procurement reform aimed squarely at UK suppliers.
What are the opportunities for life sciences suppliers
The UK Modern Industrial Strategy and the Life Sciences Sector Plan set out 33 actions, with several aimed directly at manufacturing and the supply chain.
Manufacturing and onshoring. A £520 million Life Sciences Innovative Manufacturing Fund is set up to bring globally mobile manufacturing investment to the UK, build sovereign capability, and improve supply chain resilience by onshoring critical elements of the value chain. The government is also developing a bespoke approach to supporting investments over £250 million.
Procurement reform that opens the door to suppliers. A growth mandate is being placed on NHS commercial activity, including NHS Supply Chain, which handles well over half of NHS medical device spend. New mechanisms, a Rules Based Pathway, Value Based Procurement, and the flexibility of the Procurement Act 2023, are designed to give innovators lower-friction access to the NHS and reduce duplicated evaluations.
Access to finance. The British Business Bank's £4 billion of Industrial Strategy Growth Capital is expected to crowd in £12 billion of private investment, and UK Export Finance has up to £80 billion to back exporters. A new Supply Chain Centre will work with business to build resilient supply chains.
Research, data, and trials. Up to £600 million, alongside the Wellcome Trust, is establishing a Health Data Research Service, and the government has committed to cutting commercial clinical trial set-up times to under 150 days by March 2026, with at least £30 million backing translational research networks.
Clusters and places. Life sciences manufacturing investment is being steered into clusters across the UK, from a £250 million innovation campus in West Yorkshire to manufacturing investments such as Ipsen's £86 million expansion at its Wrexham facility.
What's live now
Already in delivery or imminent: the £520 million Innovative Manufacturing Fund, the Health Data Research Service, the clinical trial set-up reforms, and Value Based Procurement pilots. The onshoring drive means primes and NHS procurement are actively looking for capable UK manufacturers and suppliers now.
The honest picture, and why it works in your favour
Life sciences is the sector where the politics have been most visible. Publication of the plan was delayed by a pricing battle between ministers and the pharmaceutical industry over a clawback tax that rose to 22.9% of UK sales (Financial Times, July 2025). And the investor Kate Bingham, former chair of the UK Covid Vaccine Taskforce, warned in the Financial Times that the plan, though bold, is "destined to disappoint unless we pick up the pace," noting that up to 40% of new drugs are never launched in the UK (Financial Times, July 2025).
For a manufacturing or engineering supplier, that tension is mostly upstream of you. The pricing fight is between pharma and the NHS; the supply chain and onshoring opportunity, the £520 million manufacturing fund, the procurement reforms, the push for domestic capability, is more concrete and less contested. The companies that get found and verified first will win the manufacturing and device work as it is brought back onshore. That is the case for being visibly ready now.
What to do now
We apply a structured 3-step process to ensure your company shows up and stands out from the first supplier search to the final shortlist. Carbon Fibre Tubes is a good example. Their composite tubes are used in medical applications, and our marketing helps them reach new buyers across the life sciences sector.
Step 1: Foundations and conversion
Step 2: Trust and consideration
Step 3: Awareness and network scaling
This is the heart of our B2B lead generation work for manufacturing and engineering companies: turning the investment this strategy is creating into qualified enquiries.
Get quarterly email updates when funding applications are announced
New schemes, deadlines, and investment commitments land every quarter. Join our mailing list and we'll send you the updates that matter for your sector as they're announced, so you don't have to keep track and read all the new documentation yourself.
Prefer to talk it through first? Book a call with Simon.
Let's talk
You can speak with Simon Batchelar, Co-Founder and Marketing Strategy Consultant at Pallant, who has prepared this analysis and can discuss how your business can position itself to benefit from the funding and support available.
Sources and further reading
- UK Modern Industrial Strategy (full policy paper)
- Life Sciences Sector Plan
- Industrial Strategy Sector Plans
- Quarterly update: July to September 2025
- Commentary (Financial Times): Life sciences plan delayed over pricing battle with pharma industry (July 2025) and The UK needs to pick up the pace on life sciences (July 2025).
Last reviewed June 2026. We update this analysis as the government publishes new commitments and quarterly delivery data.